[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Teo T, Wee SB: Clinically 'benign' breast lumps: sarcoma in hiding?--Case reports and literature review. Ann Acad Med Singapore; 2004 Mar;33(2):270-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically 'benign' breast lumps: sarcoma in hiding?--Case reports and literature review.
  • Breast sarcoma is a very rare entity that accounts for less than 1% of all breast malignancies and less than 5% of all soft tissue tumours.
  • The aim is to emphasise their apparent benign appearance on physical examination, so that readers will be alerted in a similar clinical setting.
  • Medline was used to search for relevant articles concerning the pathology, treatment modalities and long-term prognosis of patients with this rare illness.
  • We also reviewed soft tissue sarcomas found elsewhere.
  • Articles relating to phyllodes tumour were excluded or only relevant sections used.
  • Despite conflicting reports and lack of clinical studies, we believe that a simple mastectomy will suffice as adequate treatment, hence avoiding the undesirable side effects of chemotherapy or radiotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15098648.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 22
  •  go-up   go-down


2. Osaka S, Sugita H, Osaka E, Yoshida Y, Ryu J: Surgical management of malignant soft tissue tumours in patients aged 65 years or older. J Orthop Surg (Hong Kong); 2003 Jun;11(1):28-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of malignant soft tissue tumours in patients aged 65 years or older.
  • OBJECTIVE: With the aim to determine the most effective treatment for primary malignant musculoskeletal tumours in patients aged 65 years or older, we reviewed cases of low- and high-grade neoplasms, surgical margins, surgical methods, and the prognoses of elderly and aged patients at our institution.
  • METHODS: Records of 25 patients aged 65 years or older who had malignant soft tissue tumours from December 1986 to February 1997 were reviewed.
  • Low- and high-grade neoplasms accounted for 8 and 17 patients, respectively.
  • As adjuvant therapy, radiotherapy was used in 5 cases and chemotherapy in 3.
  • There was no recurrence in patients with wide surgical margins (determined on the basis of gross inspection of the excised tumour and the cut surface); but there was recurrence in 4 patients with marginal margins, and one patient with intralesional margin.
  • The overall 5-year survival rate was 79.6%; for low- and high-grade neoplasms, the figures were 100% and 69.7%, respectively; for those aged 65 to 69 years and in their 70's or older, the figures were 90.9% and 70.1%, respectively.
  • CONCLUSION: For geriatric patients, wide surgical margins are required to manage both low- and high-grade neoplasms, in order to avoid multiple surgeries.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local / surgery. Orthopedic Procedures. Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810968.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Tanaka K, Yoshikawa R, Yanagi H, Gega M, Fujiwara Y, Hashimoto-Tamaoki T, Hirota S, Tsujimura T, Tomita N: Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J Surg Oncol; 2008;6:17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug.
  • BACKGROUND: Desmoid tumours or fibromatoses are rare entities characterized by the benign proliferation of fibroblasts, which can be life-threatening due to their locally aggressive properties.
  • Surgery is widely accepted as the first line of treatment for extra-abdominal desmoids; however, it is not recommended for intra-abdominal desmoids because of the high-risk of recurrence and difficulties with the operation.
  • Here, we report on a patient with sporadic intra-abdominal desmoid tumours, who showed partial response following the intake of non-steroidal anti-inflammatory drugs.
  • Computed tomography showed an abnormal multilocular soft-tissue mass (95 x 70 mm) in the right pelvis, which was revealed by biopsy to be a desmoid tumour.
  • Immunohistochemical analysis showed that the tumour cells expressed vimentin, but not smooth-muscle actin, CD34, or desmin.
  • Non-cytotoxic treatment with etodolac (200 mg/day) was chosen because of the patient's age, lack of bowel obstruction, and the likelihood of prostate cancer.
  • Two years after the commencement of non-steroidal anti-inflammatory drug administration, computed tomography showed a decrease in tumour size (63 x 49 mm), and the disappearance of intratumoural septa.
  • CONCLUSION: Our case report suggests that non-steroidal anti-inflammatory drug treatment should be taken into consideration for use as first-line treatment in patients with sporadic intra-abdominal desmoid tumours.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Fibromatosis, Abdominal / drug therapy. Fibromatosis, Aggressive / drug therapy
  • [MeSH-minor] Aged. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):451-60 [11313976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):181-90 [12562642.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):102-5 [16382119.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5079-82 [8221638.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18567-71 [16352713.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • (PMID = 18257933.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Other-IDs] NLM/ PMC2270274
  •  go-up   go-down


Advertisement
4. Jannasch O, Evert M, Rapp L, Lippert H, Meyer F: [Current diagnosis and treatment of desmoid tumours in patients with familial adenomatous polyposis - the surgical view]. Zentralbl Chir; 2010 Feb;135(1):34-43
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current diagnosis and treatment of desmoid tumours in patients with familial adenomatous polyposis - the surgical view].
  • [Transliterated title] Aktuelle Diagnostik und Therapie von Desmoidtumoren bei Patienten mit familiärer adenomatöser Polyposis - aus chirurgischer Sicht.
  • Based on a representative selection of relevant references, the aim of this study was to reflect the change of the algorithm in the surgical management of desmoid tumours (DT) in cases of accompanying familial adenomatous polyposis (FAP).
  • Main focus is concerned with the basics of differential treatment, including additional considerations on epidemiology, diagnosis, outcome and follow-up.
  • DT are rare benign tumours that do not metastasise but tend to invade locally.
  • In contrast to the general population, DT in patients with FAP are more common, show a different pattern of tumour sites and cause considerable morbidity and mortality.
  • Most DT occur in the abdominal cavity and account for the majority of serious problems.
  • Genetic disposition and hormonal factors as well as prior surgical trauma are considered causative for the development of DT.
  • Characteristic symptoms are abdominal pain, nausea and vomiting but DT may also present as acute abdomen.
  • CT scan determines localisation and extension of the tumour.
  • Treatment includes various strategies of medication, surgical resection and radiation.
  • Data concerning diagnostic and therapeutic procedures are based on studies with small case series or case reports only.
  • [MeSH-major] Abdominal Neoplasms / surgery. Adenomatous Polyposis Coli / surgery. Fibromatosis, Aggressive / surgery. Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Connective Tissue / pathology. Diagnosis, Differential. Diagnostic Imaging. Humans. Muscles / pathology. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart, New York.
  • (PMID = 19908178.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 71
  •  go-up   go-down


5. Poprach A, Michalová E, Pavlík T, Lakomy R, Vyskocil J, Nemeccek R, Zaloudík J, Vyzula R, Kocák I, Kocáková I: [Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno]. Klin Onkol; 2008;21(3):116-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemoresistance assay results may play a role in cancer management decision process.
  • Five groups of different types of cancer in particular clinical stages were defined for chemosensitivity testing with:.
  • (1) metastatic malignant melanoma, (2) soft tissue sarcoma (STS), either primary or recurrent/metastic, (3) primary or metastatic renal cancer, (4) recurrent ovarian cancer and (5) other diagnosis "on clinician's request".
  • Sensitivity to certain chemotherapy agent observed ex vivo does not necessarily mean that the cancer would also be sensitive to the same agent in vivo, however, ex vivo resistance with following in vivo sensitivity of the tumour has not been observed to date.
  • The cultivation of malignant cells is very uncertain in solid tumours, which consist of several malignant cell multiclones (benign/stromal cells may outgrow malignant cells).
  • [MeSH-major] Drug Screening Assays, Antitumor
  • [MeSH-minor] Drug Resistance, Neoplasm. Female. Humans. Kidney Neoplasms / drug therapy. Melanoma / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097421.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


6. Ray-Coquard I, Ranchère-Vince D, Thiesse P, Ghesquières H, Biron P, Sunyach MP, Rivoire M, Lancry L, Méeus P, Sebban C, Blay JY: Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer; 2003 Sep;39(14):2021-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses.
  • Open biopsy is recommended for a soft-tissue sarcoma (s-t-S) diagnosis.
  • Core needle biopsy (CNB) was recently associated with minimal morbidity, cost and time-consumption, but also potential inaccuracy.
  • Its diagnostic utility was investigated retrospectively in 110 patients with soft-tissue masses (s-t-M) undergoing CNB between September 1994 and September 2000.
  • Sensitivity (Se), specificity (Sp), positive (PPV) and negative (NPV) predictive values were determined for malignancy (benign/malign), soft-tissue tumour (yes/no), and sarcoma diagnosis (yes/no), comparing CNB and the best standard test available; concordance was evaluated.
  • Final diagnosis was 23 benign tumours (19%), 65 s-t-S (59%), 9 lymphomas (8%), 6 fibromatoses (desmoid) (5%) and 7 carcinomas (6%).
  • CNB Sp and PPV were 100%, Se was 95, 99 and 92%, and NPV 85, 95 and 88% for diagnosing malignancy, soft-tissue tumour and sarcoma.
  • CNB Se and NPV were 100% for malignancy, connective tumour and sarcoma in lymphomas, high-grade sarcomas and desmoid tumours.
  • In low grade sarcomas, Se was 94 and 85%, and NPV 84 and 77% for malignancy and sarcoma.
  • CNB is accurate, not misleading for s-t-M diagnosis, avoids open biopsy complications, and allows one-surgery or neo-adjuvant chemotherapy planning when combined with appropriate imaging.
  • [MeSH-major] Biopsy / methods. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12957456.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the face: report of a case.
  • BACKGROUND: Soft tissue sarcomas in the head and neck region are rare and often present a difficult differential diagnosis.
  • The aim of our presentation is to point out the complexity of the diagnosis, treatment and follow up.
  • CASE PRESENTATION: An eighty-seven year old female patient was referred to our unit with a fast growing brownish lump on the face.
  • Four months beforehand, a benign fibrous histiocytoma (BFH) had been removed from the same location by excision biopsy with wide tumour-free resection margins.
  • Radical tumour resection was completed by extended parotidectomy and neck dissection; the skin defect was covered by a regional bi-lobed flap.
  • No adjuvant radio- or chemotherapy was administered.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


8. O'Donnell TM, Devitt AT, Kutty S, Fogarty EE: Recurrent congenital haemangiopericytoma in a child. J Bone Joint Surg Br; 2001 Mar;83(2):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A five-day-old boy was referred with a soft-tissue mass in his right upper arm.
  • Open biopsy confirmed the diagnosis of congenital haemangiopericytoma.
  • After MRI and selective angiography, excision biopsy was carried out, but no adjuvant therapy was administered.
  • At further examination, four years and ten months later, he was noted to have three small nodules at the site of the original tumour.
  • Congenital haemangiopericytoma is a rare cause of a soft-tissue mass in children.
  • Most tumours are benign, and recurrence is uncommon.
  • The treatment is controversial, but most centres recommend the use of adjuvant chemotherapy, combined with complete excision.
  • We recommend treatment with doxorubicin.
  • Orthopaedic surgeons should be familiar with this tumour since 30% to 50% of cases occur in the limbs.
  • [MeSH-major] Hemangiopericytoma / congenital. Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Arm. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284579.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Basu S, Nair N, Banavali S: Uptake characteristics of fluorodeoxyglucose (FDG) in deep fibromatosis and abdominal desmoids: potential clinical role of FDG-PET in the management. Br J Radiol; 2007 Sep;80(957):750-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this preliminary report, we explore the uptake pattern of fluorodeoxyglucose (FDG) in fibromatosis and hypothesize the potential clinical role of FDG-positron emission tomography (PET) in the management of this benign but locally aggressive heterogeneous group of soft-tissue tumours.
  • Treatment monitoring with chemotherapy was carried out in two cases: the reduction in FDG uptake was consistent with the histological evidence of fibrosis and reduction in mitosis.
  • Hence, a baseline FDG-PET can serve a valuable role in monitoring the effect of systemic pharmacotherapy in patients with recurrent progressive disease after unsuccessful local-regional treatment.
  • The findings in this report can be extrapolated and have implications for studying the utility of FDG-PET in defining aggressiveness, guiding biopsy and defining excision site in a large tumour and in monitoring therapy in fibromatosis.
  • [MeSH-major] Bone Neoplasms. Fibroma. Fluorodeoxyglucose F18. Muscle Neoplasms. Radiopharmaceuticals
  • [MeSH-minor] Adult. Female. Fibromatosis, Abdominal / complications. Fibromatosis, Abdominal / radiography. Fibromatosis, Abdominal / radionuclide imaging. Gardner Syndrome / complications. Humans. Male. Positron-Emission Tomography. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709361.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Treatment is controversial, with topical chemotherapy, radiotherapy, immunotherapy and radical surgery all having been employed.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • CONCLUSION: Pre-operative chemoradiation has proved to be useful in management for histologically proven benign BLT
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Condylomata Acuminata / therapy. Neoadjuvant Therapy. Perineum / pathology. Perineum / surgery. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Pirayesh A, Chee Y, Helliwell TR, Hershman MJ, Leinster SJ, Fordham MV, Poston GJ: The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol; 2001 Aug;27(5):491-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature.
  • AIM: Ten percent of soft tissue sarcomas (STS) arise in the retroperitoneal tissues.
  • The prognosis for patients with retroperitoneal sarcoma is poor with a 5-year survival rate between 12% and 70%.
  • Stage at presentation, high histological grade, unresectable primary tumour and incomplete resection are associated with a less favourable outcome.
  • Patient, tumour and treatment variables were analysed including use of adjuvant therapy and survival status.
  • Ten patients presented with pain, seven with an abdominal mass, other presentation included weight loss and haematuria.
  • Six primary tumours were completely excised, five patients received radiotherapy and five received chemotherapy.
  • Five patients received radiotherapy and five received chemotherapy.
  • Adjuvant therapy was not associated with higher survival rates.
  • Adjuvant radiotherapy and chemotherapy do not appear to be any proven benefit and the single most important prognostic factor is aggressive successful en bloc resection of the primary tumour.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neurilemmoma / surgery. Prognosis. Retrospective Studies. Sarcoma / surgery. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11504522.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 53
  •  go-up   go-down


12. Tolan S, Shanks JH, Loh MY, Taylor B, Wylie JP: Fibromatosis: benign by name but not necessarily by nature. Clin Oncol (R Coll Radiol); 2007 Jun;19(5):319-26
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromatosis: benign by name but not necessarily by nature.
  • Aggressive fibromatoses, also known as desmoid tumours, are rare fibrous tissue proliferations with a tendency for slow, local infiltrative growth.
  • Magnetic resonance imaging is the method of choice for diagnosis, pre-treatment planning and post-treatment follow-up.
  • Surgical excision with a wide margin is the treatment of choice.
  • Treatment is now planned using modern three-dimensional conformal techniques, similar to those used in soft tissue sarcoma management.
  • There is no definite dose-response relationship, but doses of 50-60 Gy in 1.8-2 Gy fractions are recommended.
  • Systemic therapy has been used for lesions not controlled by surgery or radiotherapy, or less commonly, as a primary treatment.
  • Tamoxifen and non-steroidal anti-inflammatory agents are used most often as they are relatively non-toxic, but there is limited experience with cytotoxic chemotherapy and biological agents.
  • There are no randomised trials to help guide the management of this locally aggressive 'benign' tumour and treatment decisions are best made by the local soft tissue sarcoma multidisciplinary team.
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / therapy
  • [MeSH-minor] Diagnosis, Differential. Dose Fractionation. Humans. Magnetic Resonance Imaging. Radiotherapy / methods. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419039.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


13. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg; 2004 Feb;91(2):242-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent tumour-produced angiogenic factor.
  • In this study serum levels of VEGF were measured before treatment and during follow-up in patients undergoing primary treatment for suspected soft tissue sarcoma (STS) to assess the value of serum VEGF as a tumour marker.
  • METHODS: Between April 2001 and September 2002, serum VEGF levels were analysed prospectively in 144 patients undergoing primary treatment (surgery, 123; cytotoxic chemotherapy, ten; oral imatinib, eight; radiotherapy, three) for suspected soft tissue sarcoma.
  • Serum VEGF was measured by immunoassay before treatment, in the immediate postoperative interval in patients undergoing surgery, and during follow-up.
  • RESULTS: Median pretreatment serum VEGF levels were significantly raised in patients with grade 2 and grade 3 sarcomas compared with concentrations in patients with benign lesions (413 and 467 versus 233 pg/ml respectively; P=0.007 and P=0.003 respectively).
  • In patients with tumours that had a high level of VEGF expression before treatment, follow-up measurements reflected disease status after treatment.
  • CONCLUSION: Serum VEGF expression correlated with grade in soft tissue sarcoma and reflected response to treatment.
  • [MeSH-major] Biomarkers, Tumor / blood. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Gastrointestinal Neoplasms / drug therapy. Humans. Imatinib Mesylate. Immunoassay / methods. Piperazines / therapeutic use. Platelet Count. Prospective Studies. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 14760675.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 0 / Vascular Endothelial Growth Factor A; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


14. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P: Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly; 2004 Mar 20;134(11-12):145-53
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gastrointestinal stromal tumors: from diagnosis to treatment.
  • Most gastrointestinal soft tissue neoplasms, previously classified as leiomyomas, schwannomas, leiomyoblastomas or leiomyosarcomas, are today classified as GIST on the basis of molecular and immunohistological features.
  • However, these tumours span a wide clinical spectrum from benign to highly malignant.
  • Prognostic factors have recently been identified for GIST and include tumour size, mitotic rate and other minor factors.
  • At present, surgery is the standard treatment for primary resectable GIST.
  • Benign GIST have an excellent prognosis after primary surgical treatment, with over 90% 5-year survival.
  • While recurrent or malignant GIST, which are resistant to radiotherapy and chemotherapy, had until recently an extremely poor prognosis even after surgical resection, with median survival of 12 months.
  • The development of a tyrosine kinase inhibitor has changed the management of unresectable malignant cases.
  • This paper reviews the literature and our experience of GIST, including: diagnosis, pathology, treatment and prognosis.
  • [MeSH-major] Gastrointestinal Neoplasms
  • [MeSH-minor] Algorithms. Antineoplastic Agents. Benzamides. Humans. Imatinib Mesylate. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Invasiveness. Piperazines / therapeutic use. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Stromal Cells / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106018.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 84
  •  go-up   go-down


15. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • Paraffin embedded tumour specimens were immunohistochemically stained for S-100, p53 and Ki67/MIB-1.
  • Four tumours were localised at the head & neck region, three were found in the extremities and one tumour was located on the trunk.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • The Ki67/MIB-1 proliferation index was detectable in all tumour samples, it differed from 10-30%.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


16. Burak Z, Ersoy O, Moretti JL, Erinç R, Ozcan Z, Dirlik A, Sabah D, Basdemir G: The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med; 2001 Sep;28(9):1341-50
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
  • The occurrence of multidrug resistance (MDR), which is in part due to the overexpression of P-glycoprotein (Pgp), is a major problem in neoadjuvant therapy of malignant musculoskeletal tumours.
  • We aimed to compare 99mTc-MIBI uptake and washout kinetics with the expression of Pgp and with chemotherapy response.
  • From the dynamic images, a tumour perfusion index (TPI) was obtained using Patlak-Rutland analysis.
  • Tumour to background (T/B) ratios of both early and delayed images and percent wash-out rate (WR%) of 99mTc-MIBI were calculated.
  • After neoadjuvant therapy, tumour response was assessed by examining the ratio of viable cells and by detecting percent necrosis.
  • Scintigraphic results were compared with Pgp status and therapy response.
  • We observed a positive correlation between WR% and Pgp status (r=0.61, P<0.01), and the wash-out rate of 99mTc-MIBI was significantly higher in patients with high Pgp expression than in those with a low Pgp score (33% +/- 9% vs 17% +/- 9%).
  • Therapy response was determined in 21 of 25 patients, and in only 5 of 21 cases was the percent necrosis more than 90%.
  • Neither Pgp expression rate nor WR% was found to show a significant correlation with percent necrosis in the bulk tumour specimens.
  • In conclusion, the initial uptake of 99mTc-MIBI in bone and soft tissue sarcomas did not correlate with Pgp expression.
  • A relationship was found between the wash-out rate of 99mTc-MIBI and the Pgp score, with a significant difference in WR% being observed between patients with high and patients with low Pgp expression.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. P-Glycoprotein / analysis. Radiopharmaceuticals. Sarcoma / radionuclide imaging. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Drug Resistance, Multiple. Female. Histiocytoma, Benign Fibrous / chemistry. Histiocytoma, Benign Fibrous / radionuclide imaging. Histiocytoma, Benign Fibrous / therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Osteosarcoma / chemistry. Osteosarcoma / radionuclide imaging. Osteosarcoma / therapy. Phenotype

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11585293.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


17. Junginger T, Kettelhack C, Schönfelder M, Saeger HD, Rieske H, Krummenauer F, Hermanek P: [Therapeutic strategies in malignant soft tissue tumors. Results of the soft tissue tumor register study of the Surgical Oncology Working Group]. Chirurg; 2001 Feb;72(2):138-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategies in malignant soft tissue tumors. Results of the soft tissue tumor register study of the Surgical Oncology Working Group].
  • [Transliterated title] Therapeutische Strategien bei malignen Weichteiltumoren. Ergebnisse der Weichteiltumor-Registerstudie der CAO.
  • INTRODUCTION: This study, carried out by the Surgical Oncology Working Group (CAO) of the German Society for Surgery, was performed to analyse the strategies in the treatment of soft tissue sarcomas in adults.
  • METHODS: In a period of 19 months the data on 292 patients suffering from soft tissue sarcomas, treated in 99 surgical departments in Germany, were analysed prospectively.
  • A special questionnaire was developed including pretherapeutic biopsy, previous treatment, definitive surgical treatment, combined modality approach and histopathological results.
  • Limb-sparing treatment was performed in 96% of the extremity tumours.
  • In spite of less radical treatment in tumours of the trunk, additional radiotherapy was not more frequently performed.
  • CONCLUSION: To improve the quality in the treatment of soft tissue sarcomas it seems to be of great importance to avoid inadequate initial treatment (18%), to respect the rules of oncological surgery (tumour rupture in 7% of cases), to improve the histopathological examination (no R classification in 5-12%) and to develop guidelines for multimodality treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Nerve Sheath Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Germany. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / radiotherapy. Liposarcoma / surgery. Liposarcoma, Myxoid / drug therapy. Liposarcoma, Myxoid / radiotherapy. Liposarcoma, Myxoid / surgery. Lymph Node Excision. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Registries. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11253672.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Raguse JD, Gath HJ, Oettle H, Bier J: Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg; 2004 Sep;33(6):606-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive fibromatosis is the name for uncommon soft-tissue neoplasms arising within musculoaponeurotic tissue.
  • They show benign histologic features but have an aggressive local behaviour and frequently recur after surgery or radiation.
  • A slow but steady reduction of the tumour was observed, and pre-existing symptoms disappeared.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Fibromatosis, Aggressive / drug therapy. Head and Neck Neoplasms / drug therapy. Interferon-alpha / administration & dosage
  • [MeSH-minor] Female. Humans. Injections, Subcutaneous. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Recombinant Proteins

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15308262.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


19. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • In the group of mature teratomas the "dermoid cyst" appears as a benign subtype mostly observed in children.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


20. Pellegrino M, Vadrucci S, Tinelli A: [Angiomyofibroblastoma of the vulva: a rare but distinct entity. Case report and literature review]. Pathologica; 2007 Dec;99(6):438-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyofibroblastoma is a benign vulvar tumour involving soft tissue that is characterized by alternating hypocellular and hypercellular areas of spindle stromal cells, admixed and aggregated around blood vessels.
  • It is important to recognize this entity as it shows benign behaviour with respect to other mesenchymal tumours of the vagina, which have a more aggressive behaviour.
  • [MeSH-major] Angiofibroma / pathology. Angiomyoma / pathology. Hemangioblastoma / pathology. Neoplasms, Second Primary / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416337.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Number-of-references] 7
  •  go-up   go-down


21. Landen S, Ballet T, Kessler R, Badic B, Costache M, Dobos S, Delugeau V: Tuberculosis diagnosed after major hepatectomy for suspected malignancy. Acta Chir Belg; 2010 Mar-Apr;110(2):221-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with a history of surgery and adjuvant chemotherapy 2 1/2 years previously for Dukes C colonic adenocarcinoma was diagnosed with a focal liver lesion on follow-up examinations.
  • Ultrasound and computed tomography scan revealed a 3.8 cm soft tissue mass.
  • Positron emission tomography scan showed intense uptake, corroborating the diagnosis of a colonic liver metastasis.
  • Major hepatectomy was performed but pathology revealed that the lesion was in fact a benign tuberculosis pseudo-tumour.
  • In developed countries liver tuberculosis remains extremely rare, particularly the macronodular form.
  • The diagnosis is often made only after hepatectomy for suspected malignancy.
  • The increasing use of potent anticancer chemotherapy may favour the reactivation of quiescent tuberculosis, posing a difficult differential diagnosis with liver metastases.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / diagnosis. Tuberculosis, Hepatic / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Aged. Colonic Neoplasms / complications. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514839.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


22. Klenke FM, Merkle T, Fellenberg J, Abdollahi A, Huber PE, Gebhard MM, Ewerbeck V, Sckell A: A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim; 2005 Oct;39(4):377-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although up to 85% of the most frequently occurring malignant solid tumours, such as lung and prostate carcinomas, metastasize into the bone, and despite the knowledge that a tumour's course may be altered by its surrounding tissue, there is no adequate experimental model available enabling the investigation of orthotopically grown bone tumours in vivo.
  • Intravital microscopy is an internationally accepted experimental method, used in various acute and chronic animal models, that enables qualitative and quantitative analysis of the angiogenesis, microcirculation, growth behaviour, etc. of various benign and malignant tissues.
  • Additionally, tissue samples can be taken after termination of the in vivo experiments for further ex vivo investigation (histology, immunohistochemistry, molecular biology, etc.
  • Severe combined immunodeficient mice were fitted with a cranial window preparation where the calvaria served as the site for orthotopic implantation of the solid human tumours Saos-2 osteosarcoma (primary) and A 549 lung carcinoma and PC-3 prostate carcinoma (secondary).
  • Histological assessment confirmed the data obtained in vivo, showing typical tumour growth with infiltration of the surrounding osseous and soft tissues.
  • This novel model serves as a valuable tool in understanding the biology of primary and secondary bone tumours in physiological and pathophysiological situations, with implications for the most areas of tumour therapy such as chemotherapy, radiation and antiangiogenesis.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Animals. Lung Neoplasms / pathology. Male. Mice. Mice, SCID. Microscopy, Fluorescence. Microscopy, Video. Neoplasm Transplantation. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197704.001).
  • [ISSN] 0023-6772
  • [Journal-full-title] Laboratory animals
  • [ISO-abbreviation] Lab. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Colagrande S, Carbone SF, Carusi LM, Cova M, Villari N: Magnetic resonance diffusion-weighted imaging: extraneurological applications. Radiol Med; 2006 Apr;111(3):392-419
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With regard to the latter, although there are differences between benign forms [focal nodular hyperplasia (FNH), adenoma] and malignant forms [metastasis, hepatocellular carcinoma (HCC)] in their apparent diffusion coefficient (ADC) in the average values for histological type, there is a significant overlap in values when lesions are assessed individually, with the consequent problem of their correct identification.
  • Attempts have therefore been made to use Dw imaging in the characterization of soft-tissue tumours although the findings so far have been disputed.
  • Greater agreement has been found regarding sensitivity of the technique in assessing response of these tumours to chemotherapy: tumour necrosis is thought to increase ADC whereas the persistence of vital neoplastic tissue tends to lower it.
  • One of the most promising applications of Dw imaging is without doubt the assessment of vertebral collapse where a high ADC has been shown to be associated with an osteoporotic cause and a low ADC with a neoplastic cause.
  • Nonetheless, even here, a moderate overlap between ADC values of the two types has been encountered.
  • Lastly, a significant difference in ADC values between degenerative and inflammatory effusion has been found, a fact that may be explained as the result of the activity of hyaluronidase present in inflammatory forms, which causes a reduction in the concentration of hyaluronic acid with a consequent decrease in viscosity.
  • [MeSH-minor] Bone Diseases / diagnosis. Echo-Planar Imaging. Humans. Kidney Diseases / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis. Pancreatic Diseases / diagnosis. Soft Tissue Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683086.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 63
  •  go-up   go-down






Advertisement